Henry I. Miller

Robert Wesson Fellow in Scientific Philosophy and Public Policy
Biography: 

Henry I. Miller, MS, MD, is the Robert Wesson Fellow in Scientific Philosophy and Public Policy at the Hoover Institution. His research focuses on public policy toward science and technology, encompassing a number of areas, including pharmaceutical development, genetic engineering in agriculture, models for regulatory reform, and the emergence of new viral diseases.

Miller served for fifteen years at the US Food and Drug Administration (FDA) in a number of posts. He was the medical reviewer for the first genetically engineered drugs to be evaluated by the FDA and thus instrumental in the rapid licensing of human insulin and human growth hormone. Thereafter, he was a special assistant to the FDA commissioner and the founding director of the FDA's Office of Biotechnology. During his government service, Miller participated frequently on various expert and policy panels as a representative of the FDA or the US government. As a government official, Miller received numerous awards and citations.

Since coming to the Hoover Institution, Miller has become well known not only for his contributions to scholarly journals but also for his articles and books that make science, medicine, and technology accessible. His work has been widely published in many languages. Monographs include Policy Controversy in Biotechnology: An Insider's View; To America's Health: A Model for Reform of the Food and Drug Administration; and The Frankenfood Myth: How Protest and Politics Threaten the Biotech Revolution. Barron's selected The Frankenfood Myth as one of the 25 Best Books of 2004. In addition, Miller has published extensively in a wide spectrum of scholarly journals and popular publications worldwide, including The Lancet, Journal of the American Medical Association, Science, the Nature family of journals, Chronicle of Higher Education, Forbes, National Review, Wall Street Journal, New York Times, the Guardian, Defining Ideas, and the Financial Times. He is a regulator contributor to Forbes.com and frequently appears on the nationally syndicated radio programs of John Batchelor and Lars Larson.

Miller was selected by the editors of Nature Biotechnology as one of the people who had made the "most significant contributions" to biotechnology during the previous decade. He serves on numerous editorial boards.

Filter By:

Topic

Type

Recent Commentary

Analysis and Commentary

To Fight The Scourge Of 'Superbugs', We Need A New Regulatory Pathway

by Henry I. Millervia Forbes
Friday, December 2, 2016

It was not until the years just after World War II when streptomycin, the first truly broad-spectrum antibacterial agent, came onto the market, and penicillin began to be widely available that the Golden Age of antibiotic therapy really began. Before that, even seemingly trivial infections of the skin, lungs or other organs could lead to sepsis and death.

Analysis and Commentary

Zzzzzzzzzzzz...Facts You Need To Know About Sleep And Sleep Disorders

by Mia Zaharna, Henry I. Millervia Forbes
Wednesday, November 30, 2016

A certain amount of sound sleep is necessary for optimal health and can affect hormone levels, mood and weight. However, sleep problems, including snoring, sleep apnea, insomnia, sleep deprivation, and restless legs syndrome are common.

Analysis and Commentary

The EPA Shows Again That It’s An Affront To Common Sense

by Henry I. Miller, Jeff Stiervia National Review
Wednesday, November 23, 2016

It’s cooking data to justify costly regulations with disproportionately small benefits.

Blank Section (Placeholder)Analysis and Commentary

The State Vs. Zika

by Henry I. Millervia Defining Ideas
Tuesday, November 22, 2016

Partisan politics, and government waste and abuse, are preventing us from combatting the disease effectively. 

Analysis and Commentary

Will The Trump Administration Usher In An Era Of Less Cronyism And Pay-To-Play?

by Henry I. Miller, Julie Kellyvia Forbes
Wednesday, November 16, 2016

“You know I am your chief lobbyist in the campaign.” –Clinton Campaign Chairman John Podesta to Gary Hirshberg, chairman of Stonyfield Farm organic yogurt company and foe of biotechnology, in a WikiLeaks email.

Featured

When 'Bioethics' Harms Those It Is Meant To Protect

by Henry I. Millervia Forbes
Wednesday, November 9, 2016

An ex-con named James P. Morrow once sued Ohio Governor George Voinovich and 300 other officials because they allegedly tried to “beam” down security people to confront Morrow every time he entered a courthouse.

Analysis and Commentary

Gray Lady Bites Dog

by Henry I. Millervia National Review
Saturday, November 5, 2016

The Times is convinced that being licked by a dog will give you a disease. It won’t.

The New York Times' Front-Page Screwup On 'GMOs'

by Henry I. Miller
Wednesday, November 2, 2016

The New York Times has a “thing” about the genetic engineering of plants—the same sort of thing that Creationists have about Darwinism.

Analysis and Commentary

FDA’s Hostility Blocks Zika-Prevention Technology

by Henry I. Miller, Drew L. Kershenvia The Hill
Friday, October 28, 2016

There have been more than 30,000 Zika infections in U.S. states and territories. The number of locally transmitted cases–-via the bite of the Aedes aegypti mosquito--is continuing to increase, as are the known modes of transmission. 

Analysis and Commentary

PTA Fails Science, History, Economics And Common Sense

by Henry I. Miller, Andrew Seidenfeldvia Forbes
Wednesday, October 26, 2016

Kids of a certain age often think their parents are clueless. Sometimes they’re right. For considering a colossally misguided proposal that fails everything—science, history and economics, to say nothing of common sense—the New York State PTA gets an “F.”

Pages